Home › Seizures › Michigan › Detroit
Seizures clinical trials in Detroit, MI
4 studies for Seizures are looking for participants at sites in and around Detroit (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
RecruitingPhase 1
- Wayne State University, Detroit
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
RecruitingPhase 2
- Wayne State University - Detroit Medical Center, Detroit
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
RecruitingPhase 3
- Wayne State University/Detroit Medical Center Comprehensive Epilepsy Program, Detroit
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
RecruitingPhase 3
- 9D University Health Center, Detroit
About Seizures
Seizures are caused by sudden, abnormal electrical activity in the brain. They can be mild or severe. Learn about the types, causes, and treatments.
More about Seizures on MedlinePlus
Seizures trials in other cities
- Washington, DC13 studies
- New York City, NY12 studies
- Philadelphia, PA11 studies
- Houston, TX8 studies
- Boston, MA8 studies
- Birmingham, AL7 studies
- Miami, FL6 studies
- Dallas, TX6 studies
- Durham, NC6 studies
- Chicago, IL6 studies
- Cincinnati, OH6 studies
- Cleveland, OH5 studies
Other studies in Detroit
- Non-Small Cell Lung Cancer44 studies
- Breast Cancer33 studies
- Cancer (all types)29 studies
- Colorectal Cancer26 studies
- Ovarian Cancer26 studies
- Metastatic Cancer24 studies
- Prostate Cancer22 studies
- Endometrial Cancer21 studies
- Lung Cancer20 studies
- Multiple Myeloma19 studies
- Stomach Cancer16 studies
- Head and Neck Squamous Cell Carcinoma15 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.